SCHEMBL6520192

SCHEMBL6520192

O=C(O)Cc1cc(C(F)(F)F)c(Oc2ccc3[nH]cc(S(=O)(=O)c4ccc(F)cc4)c3c2)c(C(F)(F)F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 9/20 0.62
THRB P10828 9/20 0.62
SMN1; SMN2 Q16637 5/20 0.48
HTT P42858 3/20 0.48
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP9 P14780 1/20 0.36
MMP12 P39900 1/20 0.36
MMP13 P45452 1/20 0.36
MMP14 P50281 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6520233 0.94 THRB (0.56) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6516969 0.94 THRA (0.58) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6512865 0.94 THRB (0.56) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6862290 0.93 THRB (0.62) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6512608 0.93 THRA (0.65) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6511333 0.92 THRA (0.64) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6513049 0.92 THRA (0.64) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6511483 0.92 THRB (0.61) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6522242 0.90 THRA (0.50) THRATHRBSMN1; SMN2HTTKDM4E
SCHEMBL6516627 0.90 THRB (0.61) THRATHRBSMN1; SMN2HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 THRA 2460/4885THRB 1772/4885SMN1; SMN2 4749/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP THRA 1917/4885THRB 1835/4885SMN1; SMN2 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.